NASDAQ:SNDX

Syndax Pharmaceuticals Stock Insider Trading

etoro logo Buy SNDX
*Your capital is at risk
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026

Syndax Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -11.24. In total, the insiders bought 4.28M and sold 545.78K SNDX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-11.24
Buy 4.28M shares
Sell 545.78K shares
73% Buy Activity
Weak Negative Correlation
Buy Signal Low Confidence
Feb 04, 2026

Analysis Breakdown:

  • Weakened by a contradictory negative Insider Power Score.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Sep 08, 2025
Buy
Stock options (Right to buy)
M-Exempt
Metzger Michael A
Chief Executive Officer
CEO / President 157 307
Value: $1.71M
Sep 08, 2025
Buy
Stock options (Right to buy)
M-Exempt
Metzger Michael A
Chief Executive Officer
CEO / President 157 307
Value: $1.71M
Sep 08, 2025
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 157 307
Value: $2.58M
Sep 08, 2025
Buy
Common Stock
M-Exempt
Metzger Michael A
Chief Executive Officer
CEO / President 157 307
Value: $1.71M
Aug 18, 2025
Buy
Common Stock
M-Exempt
Podlesak Dennis
Director
Director 19 200
Value: $138.2K
Aug 18, 2025
Sell
Common Stock
S-Sale
Podlesak Dennis
Director
Director 19 200
Value: $304.2K
Aug 18, 2025
Buy
Stock Options (Right to buy)
M-Exempt
Podlesak Dennis
Director
Director 19 200
Value: $138.2K
Aug 18, 2025
Buy
Stock Options (Right to buy)
M-Exempt
Podlesak Dennis
Director
Director 19 200
Value: $138.2K
Aug 18, 2025
Sell
Common Stock
S-Sale
Podlesak Dennis
Director
Director 19 200
Value: $304.2K
Aug 18, 2025
Buy
Common Stock
M-Exempt
Podlesak Dennis
Director
Director 19 200
Value: $138.2K
Aug 15, 2025
Sell
Common Stock
S-Sale
Podlesak Dennis
Director
Director 19 200
Value: $298.4K
Aug 15, 2025
Sell
Common Stock
S-Sale
Podlesak Dennis
Director
Director 19 200
Value: $298.4K
Aug 14, 2025
Sell
Common Stock
S-Sale
Podlesak Dennis
Director
Director 19 200
Value: $272.5K
Aug 14, 2025
Sell
Common Stock
S-Sale
Podlesak Dennis
Director
Director 19 200
Value: $272.5K
Jul 31, 2025
Buy
Common Stock
J-Other
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 1 226
Value: $10.3K
Jul 31, 2025
Buy
Common Stock
J-Other
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 1 226
Value: $10.3K
Jul 16, 2025
Sell
Common Stock
S-Sale
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 1 296
Value: $12.0K
Jul 16, 2025
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 7 534
Value: $70.0K
Jul 16, 2025
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 7 534
Value: $70.0K
Jul 16, 2025
Sell
Common Stock
S-Sale
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 1 296
Value: $12.0K
May 19, 2025
Buy
Common Stock
P-Purchase
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 3 000
Value: $27.9K
May 19, 2025
Buy
Common Stock
P-Purchase
Huber Martin H. Jr.
Director
Director 5 000
Value: $45.0K
May 19, 2025
Buy
Common Stock
P-Purchase
Katkin Keith
Director
Director 10 000
Value: $91.1K
May 19, 2025
Buy
Common Stock
P-Purchase
Katkin Keith
Director
Director 10 000
Value: $91.1K
May 19, 2025
Buy
Common Stock
P-Purchase
Huber Martin H. Jr.
Director
Director 5 000
Value: $45.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT SYNDAX PHARMACEUTICALS INC
Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE